vs
Beneficient（BENF）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
REGENXBIO Inc.的季度营收约是Beneficient的1.6倍（$30.3M vs $18.7M），Beneficient净利率更高（106.7% vs -221.3%，领先328.0%），Beneficient同比增速更快（322.5% vs 43.0%）
Beneficient是一家专注于另类资产流动性解决方案的金融服务企业，为私募股权、对冲基金份额、实物资产等非流动资产持有者提供定制化服务，客户主要涵盖北美地区的机构投资者、高净值人士及家族办公室。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
BENF vs RGNX — 直观对比
营收规模更大
RGNX
是对方的1.6倍
$18.7M
营收增速更快
BENF
高出279.5%
43.0%
净利率更高
BENF
高出328.0%
-221.3%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $18.7M | $30.3M |
| 净利润 | $19.9M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | 21.1% | -190.0% |
| 净利率 | 106.7% | -221.3% |
| 营收同比 | 322.5% | 43.0% |
| 净利润同比 | 330.5% | -31.2% |
| 每股收益（稀释后） | — | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BENFRGNX
| Q4 25 | $18.7M | $30.3M | ||
| Q3 25 | $-2.8M | $29.7M | ||
| Q2 25 | $-12.6M | $21.4M | ||
| Q1 25 | $-31.0M | $89.0M | ||
| Q4 24 | $4.4M | $21.2M | ||
| Q3 24 | $8.6M | $24.2M | ||
| Q2 24 | $10.0M | $22.3M | ||
| Q1 24 | — | $15.6M |
净利润BENFRGNX
| Q4 25 | $19.9M | $-67.1M | ||
| Q3 25 | $-17.9M | $-61.9M | ||
| Q2 25 | $-92.6M | $-70.9M | ||
| Q1 25 | $-44.6M | $6.1M | ||
| Q4 24 | $-8.6M | $-51.2M | ||
| Q3 24 | $9.7M | $-59.6M | ||
| Q2 24 | $44.3M | $-53.0M | ||
| Q1 24 | — | $-63.3M |
毛利率BENFRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率BENFRGNX
| Q4 25 | 21.1% | -190.0% | ||
| Q3 25 | 646.5% | -176.3% | ||
| Q2 25 | 734.0% | -296.3% | ||
| Q1 25 | 146.3% | 13.6% | ||
| Q4 24 | -215.3% | -242.1% | ||
| Q3 24 | -160.2% | -256.6% | ||
| Q2 24 | — | -251.3% | ||
| Q1 24 | — | -408.8% |
净利率BENFRGNX
| Q4 25 | 106.7% | -221.3% | ||
| Q3 25 | 648.1% | -208.3% | ||
| Q2 25 | 734.0% | -331.8% | ||
| Q1 25 | 144.1% | 6.8% | ||
| Q4 24 | -195.5% | -241.3% | ||
| Q3 24 | 113.9% | -246.3% | ||
| Q2 24 | 441.1% | -237.7% | ||
| Q1 24 | — | -405.4% |
每股收益（稀释后）BENFRGNX
| Q4 25 | — | $-1.30 | ||
| Q3 25 | — | $-1.20 | ||
| Q2 25 | — | $-1.38 | ||
| Q1 25 | — | $0.12 | ||
| Q4 24 | — | $-0.99 | ||
| Q3 24 | — | $-1.17 | ||
| Q2 24 | — | $-1.05 | ||
| Q1 24 | — | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $7.9M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-128.6M | $102.7M |
| 总资产 | $337.9M | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BENFRGNX
| Q4 25 | $7.9M | $230.1M | ||
| Q3 25 | $4.9M | $274.2M | ||
| Q2 25 | $7.6M | $323.3M | ||
| Q1 25 | $1.3M | $267.9M | ||
| Q4 24 | $4.1M | $234.7M | ||
| Q3 24 | $4.5M | $255.5M | ||
| Q2 24 | $4.4M | $290.4M | ||
| Q1 24 | — | $338.7M |
股东权益BENFRGNX
| Q4 25 | $-128.6M | $102.7M | ||
| Q3 25 | $-142.8M | $161.5M | ||
| Q2 25 | $-120.4M | $213.7M | ||
| Q1 25 | $-34.9M | $274.2M | ||
| Q4 24 | $14.3M | $259.7M | ||
| Q3 24 | $-13.2M | $301.4M | ||
| Q2 24 | $-148.3M | $348.3M | ||
| Q1 24 | — | $390.7M |
总资产BENFRGNX
| Q4 25 | $337.9M | $453.0M | ||
| Q3 25 | $316.2M | $525.2M | ||
| Q2 25 | $334.5M | $581.0M | ||
| Q1 25 | $354.9M | $490.9M | ||
| Q4 24 | $400.0M | $466.0M | ||
| Q3 24 | $368.8M | $519.1M | ||
| Q2 24 | $361.3M | $569.4M | ||
| Q1 24 | — | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-9.4M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | — | $-52.8M |
| 自由现金流率自由现金流/营收 | — | -174.0% |
| 资本支出强度资本支出/营收 | 0.0% | 1.7% |
| 现金转化率经营现金流/净利润 | -0.47× | — |
| 过去12个月自由现金流最近4个季度 | — | $-126.4M |
8季度趋势，按日历期对齐
经营现金流BENFRGNX
| Q4 25 | $-9.4M | $-52.3M | ||
| Q3 25 | $-14.5M | $-56.0M | ||
| Q2 25 | $-10.8M | $-49.3M | ||
| Q1 25 | $-37.7M | $33.6M | ||
| Q4 24 | $-10.0M | $-31.6M | ||
| Q3 24 | $-8.6M | $-40.5M | ||
| Q2 24 | $-10.6M | $-45.5M | ||
| Q1 24 | — | $-55.5M |
自由现金流BENFRGNX
| Q4 25 | — | $-52.8M | ||
| Q3 25 | — | $-56.5M | ||
| Q2 25 | $-10.9M | $-49.7M | ||
| Q1 25 | $-38.8M | $32.6M | ||
| Q4 24 | $-10.0M | $-32.7M | ||
| Q3 24 | $-8.9M | $-40.9M | ||
| Q2 24 | $-11.3M | $-46.0M | ||
| Q1 24 | — | $-56.0M |
自由现金流率BENFRGNX
| Q4 25 | — | -174.0% | ||
| Q3 25 | — | -189.9% | ||
| Q2 25 | 86.6% | -232.8% | ||
| Q1 25 | 125.3% | 36.6% | ||
| Q4 24 | -227.2% | -154.2% | ||
| Q3 24 | -103.7% | -168.9% | ||
| Q2 24 | -112.6% | -206.2% | ||
| Q1 24 | — | -358.5% |
资本支出强度BENFRGNX
| Q4 25 | 0.0% | 1.7% | ||
| Q3 25 | 0.0% | 1.7% | ||
| Q2 25 | -0.8% | 1.8% | ||
| Q1 25 | -3.5% | 1.2% | ||
| Q4 24 | 1.0% | 5.1% | ||
| Q3 24 | 3.1% | 1.3% | ||
| Q2 24 | 6.6% | 2.1% | ||
| Q1 24 | — | 3.6% |
现金转化率BENFRGNX
| Q4 25 | -0.47× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | -0.88× | — | ||
| Q2 24 | -0.24× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BENF
| Ben Liquidity | $8.2M | 44% |
| Other | $7.6M | 41% |
| Ben Custody | $2.9M | 16% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
